A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer

NCT02608073 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Cancer

Interventions

DRUG: Capecitabine
DRUG: Cisplatin

Sponsor

Hoffmann-La Roche